Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash & Equivalents (2020 - 2026)

InMed Pharmaceuticals has reported Cash & Equivalents over the past 5 years, most recently at $7.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 465.96% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $7.0 million, up 465.96%, while the annual FY2025 figure was $11.1 million, 68.54% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $7.0 million at InMed Pharmaceuticals, down from $9.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $15.3 million in Q3 2021 and troughed at $1.2 million in Q4 2024.
  • A 5-year average of $7.6 million and a median of $7.0 million in 2025 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: crashed 88.58% in 2023 and later soared 465.96% in 2025.
  • Year by year, Cash & Equivalents stood at $11.3 million in 2021, then grew by 1.53% to $11.5 million in 2022, then crashed by 88.58% to $1.3 million in 2023, then fell by 5.44% to $1.2 million in 2024, then soared by 465.96% to $7.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for INM at $7.0 million in Q4 2025, $9.4 million in Q3 2025, and $11.1 million in Q2 2025.